Antibodies – VJRegenMed

CD33 CRISPR/Cas9 gene-edited donor allograft in patients with AML at risk of relapse post-HSCT

Anya Kerkache — Thu, 09 Mar 2023 11:31:49 +0000

John DiPersio, MD, PhD, Washington University School of Medicine, St. Louis, MO, shares the rationale and results of a first-in-human clinical trial evaluating the safety of trem-cel (formerly VOR33), a CD33 CRISPR/Cas9 gene-edited donor allograft designed to prevent relapse in patients with acute myeloid leukemia (AML) undergoing hematopoietic stem cell transplantation (HSCT; NCT04849910). Results from the first two patients transplanted with trem-cel indicated neutrophil engraftment and a similar platelet recovery when compared to patients who received non-edited CD34-selected grafts. Treatment with gemtuzumab ozogamicin (GO) in one of the recipients did not result in a change in blood counts, suggesting that the target was effectively eliminated on the recipient’s stem cells and that GO would then only target residual leukemia cells expressing CD33. The ability of this strategy to induce long-term remission and to effectively eliminate all residual leukemia cells remains to be confirmed. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR® held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

CAR T-cells in adult ALL

Marta Palhas — Fri, 26 Feb 2021 14:08:28 +0000

CD19-directed CAR T-cells have been approved for use in children and young adults up to the age of 25 years with acute lymphoblastic leukemia (ALL). Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, outlines the use of CAR T-cells in adult ALL. Several prognostic factors for CAR-T therapy’s success have been identified, including platelet count before CAR-T infusion, lactate dehydrogenase (LDH) level, and mutated p53. Additionally, Prof. Nagler discusses if CAR T-cells are the definitive therapy for ALL or a pathway to allogeneic transplant. Finally, Prof. Nagler shares new approaches for CAR T-cells in ALL, including CD22-directed CAR T-cells, sequential administration of CD19 and CD22 CAR T-cells, bispecific CARs, and allogeneic CAR T-cells. This interview took place during the 3rd European CAR T-cell Meeting.

A look into the future: CAR-T and bispecifics in myeloma

Marta Palhas — Fri, 26 Feb 2021 14:08:23 +0000

Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, discusses the future of CAR T-cell therapy and bispecific monoclonal antibodies in multiple myeloma. When approved, the optimal use for these therapies would be in triple-refractory myeloma patients, but these strategies will move into earlier lines of treatment in the future. Currently, ongoing clinical trials are evaluating the role of bispecifics and CAR T-cells following one/three prior lines of therapy. While other trials are evaluating the safety and efficacy of CAR T-cells in the front-line setting in patients with high-risk myeloma. Dr Mateos highlights different strategies, currently being investigated in preliminary clinical trials, to improve the efficacy of BCMA CAR T-cells. In the bispecific antibody field, new targets beyond BCMA are being investigated, including GPRC5D-directed bispecifics, as well as novel combinations of immune and targeted therapies. This interview took place during the 3rd European CAR T-cell Meeting.

Implementation of CAR T-cell therapy in myeloma: practical and patient-related aspects

Marta Palhas — Fri, 26 Feb 2021 14:08:23 +0000

Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, outlines the practical and patient-related aspects that need to be considered for the implementation of CAR T-cell therapy in multiple myeloma. In order to select the appropriate therapy for each patient, physicians need to consider different criteria, such as disease morbidity, treatment history, organ function, family and social support and quality of life. This interview took place during the 3rd European CAR T-cell Meeting.

CAR T-cell toxicity: CRS, ICANS and prolonged cytopenias

Marta Palhas — Fri, 26 Feb 2021 14:08:22 +0000

Marion Subklewe, MD, LMU Hospital Munich, Munich, Germany, discusses recognition and treatment of CAR T-cell therapy-related side effects, including novel insights into the pathophysiology of long-term cytopenias. Close monitoring and timely intervention with tocilizumab with or without corticosteroids remain the best management strategies for cytokine release syndrome (CRS). The pathogenesis of neurotoxicity is not fully understood and it remains very challenging to manage. Similar to CRS management, neurotoxicity needs to be promptly recognized. Additionally, Prof. Subklewe shares the latest updates regarding prolonged cytopenias. This interview took place during the 3rd European CAR T-cell Meeting.

Sinusoidal obstruction syndrome in patients with R/R B-cell ALL

admin_vjr_user — Thu, 08 Oct 2020 14:08:11 +0000

Valentín Ortiz-Maldonado, MD, Hospital Clinic, Barcelona, Spain, discusses sinusoidal obstruction syndrome in patients with relapsed-refractory (R/R) B-cell acute lymphoblastic leukemia (ALL) treated with ARI-0001 CAR T-cells. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

Tocilizumab: CAR T-cell therapy in DLBCL

admin_vjr_user — Thu, 08 Oct 2020 14:08:11 +0000

Matthew Frigault, MD, Massachusetts General Hospital, Boston, MA, discusses the use of tocilizumab after CAR T-cell therapy for treatment of cytokine release syndrome (CRS) in refractory diffuse large B-cell lymphoma (DLBCL) patients. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).